Cross-sectional Analysis of a Collaborative Web-Based Database for Lupus Erythematosus–Associated Skin Lesions

Moghadam-Kia, Siamak; Chilek, Katherine; Gaines, Elizabeth; Costner, Melissa; Rose, Mathew; Okawa, Joyce; Werth, Victoria P.

doi:10.1001/archdermatol.2008.594

Cited by 59 publications

(64 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both the SCLE patients in this study had psoriasiform lesions. The most common type of CCLE lesion was classic DLE (88.2%) similar to MoghadamKia et al 8 . Systemic involvements were common in ACLE and rare in CCLE.…”

Section: Discussionsupporting

confidence: 73%

See 1 more Smart Citation

Cutaneous Manifestations of Lupus Erythematosus From a Tertiary Care Centre in Coastal Kerala

James¹,

Nair²

2017

jemds

View full text Add to dashboard Cite

BACKGROUNDThe aim of this study was to describe the Lupus Erythematosus (LE)-specific and LE-nonspecific cutaneous manifestations of lupus erythematosus. MATERIALS AND METHODSCutaneous manifestations of lupus erythematosus in forty consecutive patients with LE who attended Dermatology department from January 2014 to June 2015 were studied. RESULTSMajority of the patients included in the study were female (65%). The most common age group affected was 20-40 years (47.5%). Photosensitivity was the most common symptom (45%). Forty five percent of patients in the study were diagnosed of systemic lupus erythematosus (SLE) according to the ACR criteria. LE-specific skin lesions were more common than LE-nonspecific lesions (95% vs. 40%). Chronic Cutaneous LE (CCLE) was the most common LE-specific skin lesion (85%). Only psoriasiform type of Subacute Cutaneous LE (SCLE) lesions were seen in the study group. Malar rash was the most common Acute Cutaneous LE (ACLE) lesion (87.5%). Features suggestive of systemic involvement were most commonly found in patients with ACLE and least in those with CCLE. Most common LE nonspecific lesion was non-scarring alopecia (32.5%) due to telogen effluvium. Cutaneous vascular disease in the form of palpable purpura of leucocytoclastic vasculitis (2.5%), periungual telangiectasia (7.5%), erythema multiforme (2.5%) and leg ulcers (5%) were the other LE-nonspecific skin lesions observed in the study. Patients with LEnonspecific skin lesion had more systemic involvement compared to those without it. CONCLUSION LE-specific lesions are more common and can act as a diagnostic clue for lupus. LE-nonspecific lesions are more commonly associated with systemic disease.

show abstract

Section: Discussionsupporting

confidence: 73%

“…Cardinali 13 et al (96%) and Meuth et al 10 (100%) reported similar distribution of ACLE. Most studies 8,13,14,15 report psoriasiform lesions as the commonest type of SCLE lesion. Both the SCLE patients in this study had psoriasiform lesions.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous Manifestations of Lupus Erythematosus From a Tertiary Care Centre in Coastal Kerala

James¹,

Nair²

2017

jemds

View full text Add to dashboard Cite

show abstract

“…Çalışmamızda, ortalama hastalık süresinin dört yıl gibi kısa bir süre olması nedeniyle hasar skoru yüksek bulunmamıştır. Cinsiyetin RKLASİ üzerine etkisini değerlendirdiğimizde, erkek hastaların RKLASİ hasar skoru kadın hastaların hasar skorundan istatistiksel olarak 24 SKLE'li hastalar ile SLE ve DLE grubunu karşılaştırmış ve SKLE'li hastaların KLASİ aktivite ve hasar skorunu diğer gruba göre anlamlı derecede daha yüksek bulmuşlardır. Bu çalışmada 114 hastanın 7'sini SLE oluşturmaktadır.…”

Section: Discussionunclassified

Evaluation of skin lesions of lupus with Turkish revised cutaneous lupus erythematosus disease area and severity index

Ürün¹,

Dönmez²,

Arıcan³

et al. 2014

TURKDERM

View full text Add to dashboard Cite

Background and Design:The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is used to evaluate the cutaneous manifestations in patients with lupus erythematosus (LE). In recent years, the Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI) which provides more objective assessment has been developed, but the number of studies utilizing RCLASI are limited. The aim of this study was to increase the clinical use of the RCLASI by translating this scale into Turkish and to evaluate the effects of factors, which affect CLASI, on RCLASI. Materials and Methods: The scale was translated into Turkish by using proper international translation steps. Ninety-three LE patients who were admitted to Trakya University Faculty of Medicine were included in this study. Socio-demographic and clinical characteristics of the patients were recorded. Cutaneous manifestations were calculated using RCLASI. Two scores were obtained: activity and damage scores. The relationship of the scores with patient age, gender, duration of illness, facial involvement, subtypes of LE, and antinuclear antibody, Anti-Ro/ SS-A antibody and Anti-La/SS-B antibody positivities were evaluated. Results: The mean activity and damage scores were 2.59±2.88 and 0.81±1.88, respectively. When activity and damage scores were compared between the age groups, there was no statistically significant difference. The damage scores were significantly higher in male patients than in female patients. The activity scores were statistically significantly higher in patients with disease duration of more than three years and facial involvement. There was no statistically significant difference between the subtypes of LE and the activity and damage scores. RCLASI damage scores were statistically significantly higher in Anti-La/SS-B antibody positive patients.

show abstract

“…111 In an analysis of 114 patients with CLE, there were significantly more smoking patients in the group refractory to treatment than in the nonrefractory group. 112 In summary, smoking prevalence is higher in patients with CLE than in control subjects; patients with CLE start smoking at an earlier age and smoke a higher number of cigarettes per day; smokers present with a more disseminated cutaneous disease and show less response to antimalarials than nonsmokers. If patients stop or reduce smoking, skin lesions in patients with nonresponding CLE can resolve without a change in the therapeutic regimen.…”

Section: Smokingmentioning

confidence: 91%

Cutaneous lupus erythematosus: Update of therapeutic options

Kuhn

Ruland

Bonsmann

2011

Journal of the American Academy of Dermatology

178

130

View full text Add to dashboard Cite

Cross-sectional Analysis of a Collaborative Web-Based Database for Lupus Erythematosus–Associated Skin Lesions

Cited by 59 publications

References 40 publications

Cutaneous Manifestations of Lupus Erythematosus From a Tertiary Care Centre in Coastal Kerala

Cutaneous Manifestations of Lupus Erythematosus From a Tertiary Care Centre in Coastal Kerala

Evaluation of skin lesions of lupus with Turkish revised cutaneous lupus erythematosus disease area and severity index

Cutaneous lupus erythematosus: Update of therapeutic options

Contact Info

Product

Resources

About